Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc., a leading player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2006, the company has made significant strides in developing innovative therapies for urological conditions, focusing on unmet medical needs. With a strong presence in the US and expanding operations in key international markets, Urigen is dedicated to advancing patient care through its unique product offerings. The company’s flagship product, a proprietary formulation for the treatment of bladder pain syndrome, stands out for its targeted approach and efficacy. Recognised for its commitment to research and development, Urigen Pharmaceuticals has established a solid market position, contributing to advancements in urology and enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Urigen Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Urigen Pharmaceuticals, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Urigen Pharmaceuticals, Inc.'s reported carbon emissions
Urigen Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As there are no emissions or reduction initiatives reported, it is unclear how Urigen Pharmaceuticals is addressing climate change or its carbon footprint. The lack of data may suggest an opportunity for the company to develop and communicate a clearer strategy regarding its environmental impact and sustainability commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Urigen Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
